430 related articles for article (PubMed ID: 28294689)
1. Genomics, Signaling, and Treatment of Waldenström Macroglobulinemia.
Hunter ZR; Yang G; Xu L; Liu X; Castillo JJ; Treon SP
J Clin Oncol; 2017 Mar; 35(9):994-1001. PubMed ID: 28294689
[TBL] [Abstract][Full Text] [Related]
2. Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.
Treon SP; Xu L; Guerrera ML; Jimenez C; Hunter ZR; Liu X; Demos M; Gustine J; Chan G; Munshi M; Tsakmaklis N; Chen JG; Kofides A; Sklavenitis-Pistofidis R; Bustoros M; Keezer A; Meid K; Patterson CJ; Sacco A; Roccaro A; Branagan AR; Yang G; Ghobrial IM; Castillo JJ
J Clin Oncol; 2020 Apr; 38(11):1198-1208. PubMed ID: 32083995
[TBL] [Abstract][Full Text] [Related]
3. CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Tsakmaklis N; Kanan S; Castillo JJ; Treon SP
Br J Haematol; 2015 Mar; 168(5):701-7. PubMed ID: 25371371
[TBL] [Abstract][Full Text] [Related]
4. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
5. Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
Hunter ZR; Xu L; Yang G; Tsakmaklis N; Vos JM; Liu X; Chen J; Manning RJ; Chen JG; Brodsky P; Patterson CJ; Gustine J; Dubeau T; Castillo JJ; Anderson KC; Munshi NM; Treon SP
Blood; 2016 Aug; 128(6):827-38. PubMed ID: 27301862
[TBL] [Abstract][Full Text] [Related]
6. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
7. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia.
Treon SP; Sarosiek S; Castillo JJ
Blood; 2024 Apr; 143(17):1702-1712. PubMed ID: 38211337
[TBL] [Abstract][Full Text] [Related]
8. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
[TBL] [Abstract][Full Text] [Related]
9. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
[TBL] [Abstract][Full Text] [Related]
10. Ibrutinib in previously treated Waldenström's macroglobulinemia.
Treon SP; Tripsas CK; Meid K; Warren D; Varma G; Green R; Argyropoulos KV; Yang G; Cao Y; Xu L; Patterson CJ; Rodig S; Zehnder JL; Aster JC; Harris NL; Kanan S; Ghobrial I; Castillo JJ; Laubach JP; Hunter ZR; Salman Z; Li J; Cheng M; Clow F; Graef T; Palomba ML; Advani RH
N Engl J Med; 2015 Apr; 372(15):1430-40. PubMed ID: 25853747
[TBL] [Abstract][Full Text] [Related]
11. HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
Yang G; Buhrlage SJ; Tan L; Liu X; Chen J; Xu L; Tsakmaklis N; Chen JG; Patterson CJ; Brown JR; Castillo JJ; Zhang W; Zhang X; Liu S; Cohen P; Hunter ZR; Gray N; Treon SP
Blood; 2016 Jun; 127(25):3237-52. PubMed ID: 27143257
[TBL] [Abstract][Full Text] [Related]
12. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
Cea M; Cagnetta A; Acharya C; Acharya P; Tai YT; Yang C; Lovera D; Soncini D; Miglino M; Fraternali-Orcioni G; Mastracci L; Nencioni A; Montecucco F; Monacelli F; Ballestrero A; Hideshima T; Chauhan D; Gobbi M; Lemoli RM; Munshi N; Treon SP; Anderson KC
Clin Cancer Res; 2016 Dec; 22(24):6099-6109. PubMed ID: 27287071
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenström macroglobulinaemia.
Gustine JN; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ; Xu L
Br J Haematol; 2019 Jan; 184(2):242-245. PubMed ID: 30183082
[TBL] [Abstract][Full Text] [Related]
14. Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.
Xu L; Tsakmaklis N; Yang G; Chen JG; Liu X; Demos M; Kofides A; Patterson CJ; Meid K; Gustine J; Dubeau T; Palomba ML; Advani R; Castillo JJ; Furman RR; Hunter ZR; Treon SP
Blood; 2017 May; 129(18):2519-2525. PubMed ID: 28235842
[TBL] [Abstract][Full Text] [Related]
15. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance.
Varettoni M; Zibellini S; Defrancesco I; Ferretti VV; Rizzo E; Malcovati L; Gallì A; Porta MGD; Boveri E; Arcaini L; Candido C; Paulli M; Cazzola M
Haematologica; 2017 Dec; 102(12):2077-2085. PubMed ID: 28983055
[TBL] [Abstract][Full Text] [Related]
16. Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.
Ballester LY; Loghavi S; Kanagal-Shamanna R; Barkoh BA; Lin P; Medeiros LJ; Luthra R; Patel KP
Clin Lymphoma Myeloma Leuk; 2016 Jul; 16(7):395-403.e1. PubMed ID: 27268124
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS
Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512
[TBL] [Abstract][Full Text] [Related]
18.
Gustine JN; Xu L; Tsakmaklis N; Demos MG; Kofides A; Chen JG; Liu X; Munshi M; Guerrera ML; Chan GG; Patterson CJ; Keezer A; Meid K; Dubeau T; Yang G; Hunter ZR; Treon SP; Castillo JJ
Blood Adv; 2019 Oct; 3(19):2800-2803. PubMed ID: 31570491
[No Abstract] [Full Text] [Related]
19. The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Cao Y; Hunter ZR; Liu X; Xu L; Yang G; Chen J; Patterson CJ; Tsakmaklis N; Kanan S; Rodig S; Castillo JJ; Treon SP
Leukemia; 2015 Jan; 29(1):169-76. PubMed ID: 24912431
[TBL] [Abstract][Full Text] [Related]
20. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia.
Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C
Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
